Skip to main content
Boston ScientificIn development

Boston Scientific's MedSurg Diversification Bolsters Growth Prospects

Source: Autobound Signal API · 115 signals tracked for Boston Scientific · updated

Get Boston Scientific's live signals in Claude or ChatGPT, or by API

AskWhat changed at Boston Scientific this week? Use Autobound signals for bostonscientific.com.

What happened

Boston Scientific plans three key launches for its core stone portfolio over the next two to three quarters to address portfolio gaps.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Boston Scientific 's BSX MedSurg segment continues to provide a diversified and stable revenue base. Within this, Endoscopy sales grew 7% year over year in the second quarter of 2026, driven by strong performance across the business and another better-than-expected quarter for AXIOS Stent and Delivery System. The company also received FDA clearance for RIVOS, a first-of-its-kind single device designed to consolidate multiple exchanges and simplify endoscopic ultrasound biliary drainage. Urology results fell short of its expectations, growing 1% this quarter, as the recovery in sacral neuromodulation continued to take longer than anticipated. Stone management also remained under pressure due to key portfolio gaps that the company plans to address over the next three quarters. Management now expects full-year growth in the business to be flat to low-single digits. However, Boston Scientific remains confident that the long-term trajectory in Urology will improve in 2027. Three key launches are planned for its core stone portfolio over the next two to three quarters, which should help the business move closer to market growth next year. The company has also addressed a significant disruption to its sacral neuromodulation commercial capabilities by hiring and training new clinical and sales representatives, who are now in the field. Neuromodulation sales grew 12% in the second...

Keep reading with a free account

The rest of this article, and every signal for Boston Scientific, is in your free account.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
core stone portfolio

The full record

From the Signal API record

Details

Release type
Collection

Topics and mentions

Product tags

  • general technology
  • medical

Extraction

Confidence
90%
Detected
Sep 30, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Boston Scientific and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Boston Scientific this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/765f7c9d-5e57-bc6a-7b7d-8e9683f44acb returns this record as JSON. POST /v1/companies/enrich returns every signal for bostonscientific.com.

{
  "signal_id": "765f7c9d-5e57-bc6a-7b7d-8e9683f44acb",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-30T13:44:00+00:00",
  "company": {
    "name": "Boston Scientific",
    "domain": "bostonscientific.com"
  },
  "data": {
    "url": "https://www.tradingview.com/news/zacks:5506bb40c094b:0-boston-scientific-s-medsurg-diversification-bolsters-growth-prospects/",
    "title": "Boston Scientific's MedSurg Diversification Bolsters Growth Prospects - TradingView",
    "excerpt": "Boston Scientific ’s BSX MedSurg segment continues to provide a diversified and stable revenue base. Within this, Endoscopy sales grew 7% year over year in the second quarter of 2026, driven by strong performance across the business and another better-than-expected quarter for AXIOS Stent and Delivery System. The company also received FDA clearance for RIVOS, a first-of-its-kind single device designed to consolidate multiple exchanges and simplify endoscopic ultrasound biliary drainage. Urology results fell short of its expectations, growing 1% this quarter, as the recovery in sacral neuromodulation continued to take longer than anticipated. Stone management also remained under pressure due to key portfolio gaps that the company plans to address over the next three quarters. Management now expects full-year growth in the business to be flat to low-single digits. However, Boston Scientific remains confident that the long-term trajectory in Urology will improve in 2027. Three key launches are planned for its core stone portfolio over the next two to three quarters, which should help the business move closer to market growth next year. The company has also addressed a significant disruption to its sacral neuromodulation commercial capabilities by hiring and training new clinical and sales representatives, who are now in the field. Neuromodulation sales grew 12% in the second...",
    "product": "core stone portfolio",
    "summary": "Boston Scientific plans three key launches for its core stone portfolio over the next two to three quarters to address portfolio gaps.",
    "planning": true,
    "image_url": "https://s.tradingview.com/static/images/illustrations/news-story.jpg",
    "confidence": 0.9,
    "product_data": {
      "name": "core stone portfolio",
      "full_text": "its core stone portfolio",
      "fuzzy_match": false,
      "release_type": "collection"
    },
    "product_tags": [
      "general_technology",
      "medical"
    ],
    "published_at": "2026-09-30T13:44:00Z",
    "article_sentence": "Three key launches are planned for its core stone portfolio over the next two to three quarters, which should help the business move closer to market growth next year."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.